Physician profile
Jack Test
NPI 1033648951
$1,047.71
in general payments reported to CMS, 2019-2025
10 companies · $944 in 2025
The $944 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $104 · 2025: $944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,048.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,047.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $193.28 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Amgen INC. | $191.79 | 2025 | Tavneos, Krystexxa |
| Pharmacosmos Therapeutics INC. | $175.73 | 2025 | Monoferric |
| Astrazeneca Pharmaceuticals Lp | $161.88 | 2025 | Farxiga |
| Ani Pharmaceuticals, INC. | $104.33 | 2024-2025 | Purified Cortrophin Gel |
| Otsuka America Pharmaceutical, INC. | $79.59 | 2024-2025 | Jynarque |
| Novo Nordisk INC | $53.98 | 2024-2025 | Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.39 | 2025 | Jardiance |
| Lilly USA, LLC | $23.99 | 2024 | Jardiance |
| Alexion Pharmaceuticals, INC. | $13.75 | 2025 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Test listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.